The Changing Microbiologic Epidemiology of Community-Acquired Pneumonia

References

• . File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130–141
   PubMed Web of Science ®Google Scholar
• . Fine MJ, Smith MA, Carson CA, . Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275(2):134–141
   PubMed Web of Science ®Google Scholar
• . Weite T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–79
   PubMedGoogle Scholar
• . Hoyert DL, Xu J. Deaths: preliminary data for 2011. National Vital Statistics Reports. 2012;61(6):1–52. Hyattsville, MD: National Center for Health Statistics, http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf. Accessed April 25, 2013
   Google Scholar
• . Cecere LM, Rubenfeld GD, Park DR, Root RK, Goss CH. Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia. Respiration. 2010;79(2):128–136
   PubMedGoogle Scholar
• . Mortensen EM, Kapoor WN, Chang CC, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis. 2003;37(12):1617–1624
   PubMed Web of Science ®Google Scholar
• . Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet. 2013;381(9865):496–505
   PubMed Web of Science ®Google Scholar
• . Mortensen EM, Metersky ML. Long-term mortality after pneumonia. Semin Respir Crit Care Med. 2012;33(3):319–324
   PubMed Web of Science ®Google Scholar
• . Ramirez J, Aliberti S, Mirsaeidi M, . Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47(2):182–187
   PubMed Web of Science ®Google Scholar
• . Tichopad A, Roberts C, Gembula I, . Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic. Hungary, Poland and Slovakia. PLoS One. 2013;8(8):e71375
   PubMed Web of Science ®Google Scholar
• . Ma HM, Yu HY, Woo J. Recurrent hospitalization with pneumonia is associated with a higher 1-year mortality in frail older people. Intern Med J. 2013; Aug 14 [Epub ahead of print]
   Google Scholar
• . Aliberti S, Di Pasquale M, Zanaboni AM, . Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis. 2012;54(4):470–478
   PubMed Web of Science ®Google Scholar
• . Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128(6):3854–3862
   PubMed Web of Science ®Google Scholar
• . Sanz Herrero F, Blanquer Olivas J. Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med. 2012;33:220–231
   PubMed Web of Science ®Google Scholar
• . Jenkins SG, Farrell DJ. Increase in Pneumococcus macrolide resistance, United States. Emerg Infect Dis [serial on the Internet]. August 2009. http://www.cdc.gov/eid/article/15/8/08-1187.htm. Accessed April 6, 2013
   Google Scholar
• . Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011). Diagn Microbiol Infect Dis. 2013;75(1):107–109
   PubMed Web of Science ®Google Scholar
• . Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2010;36(3):197–204
   PubMed Web of Science ®Google Scholar
• . American Association for Long-Term Care Insurance. Long-term care statistics 2009. http://www.aaltci.org/long-term-care-insurance/learning-center/long-term-care-statistics.php. Accessed January 3, 2013
   Google Scholar
• . Katopodis GD, Grivea IN, Tsantsaridou AJ, Pournaras S, Petinaki E, Syrogiannopoulos GA. Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece. BMC Infect Dis. 2010;10:351
   PubMedGoogle Scholar
• . Cardoso T, Ribeiro O, Aragão IC, Costa-Pereira A, Sarmento AE. Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study. BMC Infect Dis. 2012;12:375–385
   PubMed Web of Science ®Google Scholar
• . Tanaka J, Ishiwada N, Wada A, . Incidence of childhood pneumonia and serotype and sequence-type distribution in Streptococcus pneumoniae isolates in Japan. Epidemiol Infect. 2012;140(6):1111–1121
   PubMed Web of Science ®Google Scholar
• . Park HK, Song JU, Um SW, . Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital. Respir Med. 2010;104(11):1729–1735
   PubMed Web of Science ®Google Scholar
• . Kollef MH, Micek ST. Patients hospitalized with pneumonia: determining the need for broad-spectrum antibiotic therapy. Clin Infect Dis. 2012;54(4):479–482
   PubMedGoogle Scholar
• . Nair GB, Niederman MS. Community-acquired pneumonia: an unfinished battle. Med Clin North Am. 2011;95(4):1143–1161
   PubMedGoogle Scholar
• . Agency for Healthcare Research and Quality. Pneumonia most common reason for hospitalization. Rockville, MD: Agency for Healthcare Research and Quality, US Dept of Health and Human Services. July 2, 2008. http://archive.ahrq.gov/news/nn/nn070208.htm. Accessed January 25, 2013
   Google Scholar
• . Centers for Medicare and Medicaid Services. Readmissions reduction program. August 2012. www.cms.gov/Medicare/Medicare-fee-for-service-payment/acuteinpatientPPS/readmissions-reduction-program.html. Accessed January 16, 2013
   Google Scholar
• . Centers for Medicare and Medicaid Services. Outcomes Measures. January 2013. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/OutcomeMea-sures.html. Accessed January 16, 2013
   Google Scholar
• . Nicolau DP. Containing costs and containing bugs: are they mutually exclusive? J Manag Care Pharm. 2009;15( suppl 2):S12–S17
   Google Scholar
• . Nussenblatt V, Avdic E, Cosgrove S. What is the role of antimicrobial stewardship in improving outcomes of patients with CAP? Infect Dis Clin North Am. 2013;27(1):211–228
   PubMedGoogle Scholar
• . Christensen KL, Holman RC, Steiner CA, Sejvar JJ, Stoll BJ, Schonberger LB. Infectious disease hospitalizations in the United States. Clin Infect Dis. 2009;49(7):1025–1035
   PubMed Web of Science ®Google Scholar
• . Sato R, Gomez Rey G, Nelson S, Pinsky B. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥ 50 years. Appl Health Econ Health Policy. 2013;11(3):251–258
   PubMedGoogle Scholar
• . Huang CY, Chang L, Liu CC, et al; on behalf of the Taiwan Pediatric Infectious Disease Alliance. Risk factors of progressive community-acquired pneumonia in hospitalized children: A prospective study. J Microbiol Immunol Infect. 2013; Aug 28 [Epub ahead of print]
   Google Scholar
• . Mandell LA, Wunderink RG, Anzueto A, et al, for the Infectious Diseases Society of America/American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44( suppl 2):S27–S72
   Google Scholar
• . Echols RM, Tillotson GS, Song JX, Tosiello RL. Clinical trial design for mild-to-moderate community-acquired pneumonia: an industry perspective. Clin Infect Dis. 2008;47( suppl 3):S166–S175
   PubMedGoogle Scholar
• . File TM Jr. Community-acquired pneumonia. Lancet. 2003;362(9400):1991–2001
   PubMed Web of Science ®Google Scholar
• . Wiemken TL, Peyrani P, Ramirez JA. Global changes in the epidemiology of community-acquired pneumonia. Semin Respir Crit Care Med. 2012;33(3):213–219
   PubMedGoogle Scholar
• . File TM Jr, Low DE, Eckburg PB, . Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51:1395–1405
   PubMed Web of Science ®Google Scholar
• . Moran GJ, Krishnadasan A, Gorwitz RJ, ; EMERGEncy ID NET Study Group. Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis. 2012;54(8):1126–1133
   PubMed Web of Science ®Google Scholar
• . Feikin DR Schuchat A Kolczak M, . Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health. 2000;90(2):223–229
   PubMed Web of Science ®Google Scholar
• . Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008;133(3):610–617
   PubMed Web of Science ®Google Scholar
• . Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med. 1964;60(6):759–776
   PubMedGoogle Scholar
• . Mongardon N, Max A, Bougié A, . Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care. 2012;16(4):R155
   PubMed Web of Science ®Google Scholar
• . Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother. 2002;50( suppl S1):49–59
   PubMed Web of Science ®Google Scholar
• . Chertow DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. JAMA. 2013;309(3):275–282
   PubMed Web of Science ®Google Scholar
• . Dean N. Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options. Hosp Pract (1995). 2010;38(1):7–15
   PubMedGoogle Scholar
• . Centers for Disease Control and Prevention. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae—Massachusetts, 2001–2006. Ann Emerg Med. 200&;51(3)312–314
   PubMedGoogle Scholar
• . Sharma D, Baughman W, Hoist A, . Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before the 7-valent conjugate vaccine. Pediatr Infect Dis J. 2013;32(2):e45–e53
   PubMedGoogle Scholar
• . Song JH, Dagan R, Klugman KP, Fritzeil B. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine. 2012;30(17):2728–2737
   PubMedGoogle Scholar
• . Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist. 2008;14(2):101–107
   PubMedGoogle Scholar
• . Green MC, Mason EO, Kaplan SL, . Increase in prevalence of Streptococcus pneumoniae serotype 6C at eight children's hospitals in the United States from 1993 to 2009. J Clin Microbiol. 2011;49(6):2097–2101
   PubMedGoogle Scholar
• . Jacobs MR, Bajaksouzian S, Bonomo RA, . Occurrence, distribution, and origins of Streptococcus pneumoniae Serotype 6C, a recently recognized serotype. J Clin Microbiol. 2009;47(1):64–72
   PubMedGoogle Scholar
• . McEllistrem MC, Nahm MH. Novel pneumococcal serotypes 6C and 6D: anomaly or harbinger. Clin Infect Dis. 2012;55(10):1379–1386
   PubMed Web of Science ®Google Scholar
• . Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4. Ann Clin Microbiol. 2008;7:1
   PubMedGoogle Scholar
• . Jones RN, Sader HS, Moet GJ, Farrell DJ. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998–2009). Diagn Microbiol Infect Dis. 2010;68(3):334–336
   PubMed Web of Science ®Google Scholar
• . Flamm RK, Sader HS, Farrell DJ, Jones RN. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother. 2012;56(6):2933–2940
   PubMed Web of Science ®Google Scholar
• . Pfaller MA, Farrell DJ, Sader HS, Jones RN. AWARE Ceftaroline Surveillance Program (2008–2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis. 2012;55( suppl 3):S187–S193
   PubMed Web of Science ®Google Scholar
• . Biedenbach DJ, Farrell DJ, Flamm RK, Liverman LC, McIntyre G, Jones RN. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2012;39(4):321–325
   PubMedGoogle Scholar
• . Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008–2010). Clin Infect Dis. 2012;55( suppl 3):S206–S214
   Google Scholar
• . Jacobs MR, Good CE, Windau AR, . Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 2010;54(1):2716–2719
   PubMedGoogle Scholar
• . Davies TA, Flamm RK, Lynch AS. Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. Int J Antimicrob Agents. 2012;39(6):534–538
   PubMed Web of Science ®Google Scholar
• . Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. Clin Infect Dis. 2012;55( suppl 3):S194–S205
   PubMedGoogle Scholar
• . Sader HS, Flamm RK, Farrell DJ, Jones RN. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. Clin Infect Dis. 2012;55( suppl 3):S181–S186
   PubMedGoogle Scholar
• . Diaz E, Fernandez IM, Jimenez L, Rodriguez M, Surani S. Is methicillin-resistant Staphylococcus aureus pneumonia epidemiology and sensitivity changing? Am J Med Sci. 2012;343(3):196–198
   PubMedGoogle Scholar
• . Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob Agents Chemother. 2011;55(8):3684–3690
   PubMed Web of Science ®Google Scholar
• . Jones RN, Farrel DJ, Mendes RE, Sader HS. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother. 2011;66( suppl 3):iii69–iii80
   PubMedGoogle Scholar
• . Carillo-Marquez MA, Hulten KG, Hammerman W, Lamberth L, Mason EO, Kaplan SL. Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children's Hospital. Pediatr Infect Dis J. 2011;30(7):545–550
   PubMedGoogle Scholar
• . Erdem G, Bergert L, Len K, Melish M, Kon K, Di Mauro R. Radiological findings of community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus pediatric pneumonia in Hawaii. Pediatr Radiol. 2010;40(11):1768–1773
   PubMedGoogle Scholar
• . Fridkin SK, Hageman JC, Morrison M, et al, for the Active Bacterial Core Surveillance Program of the Emergency Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14):1436–1444
   PubMedGoogle Scholar
• . Hageman JC, Uyeki TM, Francis JS, . Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis. 2006;12(6):894–899
   PubMed Web of Science ®Google Scholar
• . Kallen AJ, Brunkard J, Moore Z, . Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med. 2009;53(3):358–365
   PubMed Web of Science ®Google Scholar
• . Roberts JC, Gulino SP, Peak KK, Luna VA, Sanderson R. Fatal necrotizing pneumonia due to a Panton-Valentine leukocidin positive community-associated methicillin-sensitive Staphylococcus aureus and influenza co-infection: a case report. Ann Clin Microbiol Antimicrob. 2008;7:5
   PubMedGoogle Scholar
• . Wallin TR Hern HG, Frazee BW. Community-associated methicillin-resistant Staphylococcus aureus. Emerg Med Clin North Am. 2008;26(2):431–455
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. Severe coinfection with seasonal influenza A (H3 N2) virus and Staphylococcus aureus-Maryland, February-March 2012. MMWR Morb Mortal Wkly Rep. 2012;61:289–291
   PubMedGoogle Scholar
• . Kollef MH, Micek ST. Staphylococcus aureus pneumonia: a “superbug” infection in community and hospital settings. Chest. 2005;128(3):1093–1097
   PubMedGoogle Scholar
• . Taneja C, Haque N, Oster G, . Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. J Hosp Med. 2010;5(9):528–534
   PubMed Web of Science ®Google Scholar
• . Tadros M, Williams V, Coleman BL, . Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals. PLoS One. 2013;8(9):e75171
   PubMed Web of Science ®Google Scholar
• . Falcone M, Venditti M, Shindo Y, Kollef MH. Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia. Int J Infect Dis. 2011;15(8):e545–e550
   Google Scholar
• . Naimi TS, LeDell KH, Como-Sabetti K, . Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290(22):2976–2984
   PubMed Web of Science ®Google Scholar
• . Lessa FC, Mu Y, Ray SM, ; Active Bacterial Core surveillance (ABCs); MRSA Investigators of the Emerging Infections Program. Impact of USA300 methicillin-resistant Staphylococcus aureus on clinical outcomes of patients with pneumonia or central line-associated bloodstream infections. Clin Infect Dis. 2012;55(2):232–241
   PubMedGoogle Scholar
• . Dobler CC, Waterer G. Healthcare-associated pneumonia: a US disease or relevant to the Asia Pacific, too? Respirology. 2013;18(6):923–932
   PubMedGoogle Scholar
• . Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med. 2008;168(20):2205–2210
   PubMedGoogle Scholar
• . Woodhead M, Blasi F, Ewig S ; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect. 2011;17( suppl 6):E1–E59
   Web of Science ®Google Scholar
• . Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51(10):3568–3573
   PubMed Web of Science ®Google Scholar
• . Shorr AF, Zilberberg MD, Reichley R, . Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis. 2012;54(2):193–198
   PubMed Web of Science ®Google Scholar
• . Neidell MJ, Cohen B, Furuya Y, . Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;55(6):807–815
   PubMed Web of Science ®Google Scholar
• . Oster G, Berger A, Edelsberg J, Weber DJ. Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality. J Med Econ. 2013;16(6):809–819
   PubMedGoogle Scholar
• . Ott SR, Hauptmeier BM, Ernen C, . Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J. 2012;39(3):611–618
   PubMed Web of Science ®Google Scholar
• . Thomas R, Ferguson J, Coombs G, Gibson PG. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: a clinical audit. Respirology. 2011;16(6):926–931
   PubMedGoogle Scholar
• . Aliberti S, Peyrani P, Filardo G, . Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest. 2011;140(2):482–488
   PubMed Web of Science ®Google Scholar
• . Eckburg PB, Friedland HD, Llorens L, . Day 4 clinical response of ceftaroline fosamil versus ceftriaxone for community-acquired bacterial pneumonia. Infect Dis Clin Pract. 2012;20(4):254–260
   Google Scholar
• . Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H; CABP-ABSSSI Project Team. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis. 2012;55(8):1114–1121
   PubMed Web of Science ®Google Scholar
• . US FDA Briefing Document. Anti-infective drugs advisory committee meeting. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia and complicated skin and skin structure infections. 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycom-mittee/ucm224656.pdf. Accessed September 10, 2013
   Google Scholar
• . Capelastegui A, Espafla Yandiola PP, Quintana JM, . Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest. 2009;136(4):1079–1085
   PubMed Web of Science ®Google Scholar
• . Dharmarajan K, Hsieh AF, Lin Z, . Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355–363
   PubMed Web of Science ®Google Scholar
• . Aliberti S, Amir A, Peyrani P, . Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest. 2008;134(5):955–962
   PubMedGoogle Scholar
• . Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158–165
   PubMed Web of Science ®Google Scholar
• . Corrales-Medina VF, Suh KN, Rose G, . Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011;8(6):e1001048
   PubMed Web of Science ®Google Scholar
• . Joint Commission. Pneumonia Antibiotic Consensus Recommendations 2009. http://manual.jointcommission.org/pub/Manual/MIF0010/PN6b_Algorithm.pdf. Accessed September 28, 2012
   Google Scholar
• . Maselli DJ, Fernandez JF, Whong CY, . Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. Infect Drug Resist. 2012;5:43–51
   PubMedGoogle Scholar
• . World Health Organization. Vaccines to prevent pneumonia and improve child survival. May 2008. http://www.who.int/bulletin/volumes/86/5/07-044503/en/. Accessed April 3, 2013
   Google Scholar